A Phase 2/3 Randomized Open-Label Study of Maintenance GRT-C901/GRT-R902 A Neoantigen Vaccine in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
Brief description of study
The purpose of the study is to demonstrate clinical efficacy and characterize the clinical activity relating to the maintenance therapy with GRT-C901/GRT-R902 in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. The study drug GRT-C901/GRT-R902 is investigational, which means that the study drug has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test the study drug in the current trial.
Clinical Study Identifier: s21-01210
ClinicalTrials.gov Identifier: NCT05141721
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
